CEP-33779 (CEP33779)是一种新型、选择性的、可口服的JAK2抑制剂，IC₅₀值为1.8 nM，比对JAK1的选择性高40多倍，比对TYK2的选择性高800多倍。CEP-33779在多种肿瘤中具有抗癌和抗炎活性。

参考文献

1.Kristine L Stump, et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Research & Therapy. 2011;13:R68.

2.Tang SJ, et al. CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. Biochem Pharmacol. 2014;91(2):144-56.

3.Seavey MM, et al. Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. Mol Cancer Ther. 2012;11(4):984-93.

冰袋运输。粉末直接保存于-20℃，有效期2年。建议分装后-20℃避光保存，避免反复冻融。